7011.T (7011.T)
Quantitative Summary
DeterministicFinancial health metrics are strong: Piotroski 8/9, Altman Z 3.5 (above 3.0 safe zone threshold).
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe company exhibits a robust fundamental profile characterized by an 8/9 Piotroski F-Score, signaling strong financial health and operational momentum, while the Altman Z-Score of 3.5 suggests a comfortable distance from insolvency territory. Capital allocation efficiency is evident with an ROIC-WACC spread of +1.1%, indicating that returns on invested capital modestly exceed the cost of financing; however, this positive spread is underpinned by specific DuPont drivers where net margins sit at 4.9% and revenue growth accelerates at 8.0%. While leverage specifics are not detailed in the provided metrics, the high Piotroski score implies a favorable balance sheet structure supporting these returns without excessive risk exposure relative to peers.
Valuation dynamics present a significant divergence between current market pricing and intrinsic value models. The stock trades at a premium multiple of 54.2x earnings, which likely reflects aggressive growth expectations embedded in investor sentiment rather than immediate fundamental expansion alone. This elevated P/E ratio stands in contrast to the DCF-derived fair value estimate of $1226; without knowing the current market price or implied forward multiples, it is unclear whether the market has already priced in substantial future cash flow generation or if the high multiple represents an overvaluation relative to the calculated intrinsic worth. The gap between the 54.2x trading multiple and the DCF anchor suggests that any deviation from the assumed growth trajectory could materially impact shareholder value.
Risk assessment reveals a nuanced picture where strong financial stability metrics coexist with potentially elevated valuation risk. The combination of a high Piotroski score and positive ROIC-WACC spread provides a defensive buffer, yet the reliance on margin expansion—currently at 4.9%—to drive returns alongside revenue growth creates a sensitivity to economic headwinds that could compress profitability faster than anticipated. Investors must weigh the security offered by strong solvency indicators against the possibility that current pricing assumes perfection in maintaining both margin integrity and growth rates, leaving little room for error before valuation compression becomes a reality.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
DCF Sandbox
InteractiveSensitivity Matrix
| TG ↓ / WACC → | 6% | 7.8% | 9.8% |
|---|---|---|---|
| 2% | $1522 | $1048 | $773 |
| 3% | $1961 | $1226 | $860 |
| 4% | $2838 | $1499 | $977 |
Center = base case. Green = >10% upside, Red = >10% downside vs —.
Pre-computed DCF: WACC=7.8%, terminal growth 3%. Fair value $1226 (+0.0%). Not investment advice.
Price Chart with Moving Averages
Quant Health Deep Dive
Profitability & Value Creation
✅ Conservative payout — room for dividend increases.
Balance Sheet Health
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fundamentals
7011.T Capital Efficiency
How efficiently does 7011.T convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
7011.T converts 52% of its EBITDA into free cash flow, a healthy conversion rate indicating efficient capital management — the business generates substantial cash after reinvestment. The positive ROIC-WACC spread of 1.2% confirms that reinvested capital creates shareholder value.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Compare 7011.T to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: N/A.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.